Most side effects are: Mild to moderate in severity Digestive in nature (nausea, constipation, or diarrhea) Temporary, resolving within days to weeks Manageable with proper dosing and supportive strategies Serious side effects are rare but can include pancreatitis, gallbladder issues, or allergic reactions
In one such trial the 68-week STEP 1 study adults receiving once-weekly subcutaneous semaglutide 2.4 mg demonstrated a mean body weight reduction of 14.9%, compared with 2.4% in the placebo group [1]
In published scientific literature, DSIP is generally described as well-tolerated within research settings
Some providers prescribe semaglutide off-label for weight management
This approach pairs well with morning injection schedules
Precautions include monitoring for side effects such as nausea, vomiting, diarrhea, and potential thyroid tumors